Allogene Therapeutics announced that Geoffrey Parker, Executive Vice President and Chief Financial Officer, will retire effective November 6, 2026. Parker will continue to lead the finance organization through his retirement date as the company conducts an external search for his successor. CEO Zachary Roberts praised Parker's financial leadership during a pivotal period, and Parker expressed confidence in Allogene's strategy and pipeline. Allogene is a clinical-stage biotechnology company developing allogeneic CAR T products for cancer and autoimmune disease.
Allogene Therapeutics IncCFO retirement and external search for successor; leadership transition may create uncertainty but is not inherently negative.
